Search

Displaying results 2331 - 2340 of 5451 in total
  1. Drug

    Teprotumumab

    go.drugbank.com/drugs/DB06343
    ApprovedInvestigational

    [L11359] Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and was

  2. Drug

    Bethanechol

    go.drugbank.com/drugs/DB01019
    Approved

    Bethanechol is a synthetic ester that was initially synthesized in 1935. As a cholinergic agent, bethanechol is similar in structure and pharmacological function to acetylcholine and is used in specific cases when stimulation of the para...

    Products: Urecholine Inj 5mg/ml, Myocholine - Glenwood Tabletten 10 mg
  3. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    [A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease. … Furthermore, the pegylation of pegunigalsidase alfa promotes higher stability and a longer half-life, allowing it to reach target organs with a lower dose and frequency of administration.

  4. Drug

    Melperone

    go.drugbank.com/drugs/DB09224
    Investigational

    It has been well established in the treatment of confusion, anxiety, restlessness (particularly in the elderly) and schizophrenia as It is known to be well-tolerated with an excellent safety profile. … Recently, it has been studied as a treatment of psychosis related to Parkinson's disease [L1316].

    Products: MELPERON-NEURAX 10 MG, MELPERON-NEURAX 25 MG
  5. Drug

    Artemisia vulgaris pollen

    go.drugbank.com/drugs/DB10372
    Approved

    Artemisia vulgaris pollen is the pollen of the Artemisia vulgaris plant. Artemisia vulgaris pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS128872, Treatment Set TS343826
  6. Drug

    Etorphine

    go.drugbank.com/drugs/DB01497
    ExperimentalIllicitVet approved

    In certain countries, etorphine is classified as a Schedule 1 drug and hence, in these countries, it can be used legally only by health professionals and for research purposes.

  7. Drug

    Ticagrelor

    go.drugbank.com/drugs/DB08816
    ApprovedInvestigational

    [A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010.

    Products: BRILINTA® 90 MG, BRILINTA® 60 MG
  8. Drug

    Bromus inermis pollen

    go.drugbank.com/drugs/DB10355
    Approved

    Bromus inermis pollen is the pollen of the Bromus inermis plant. Bromus inermis pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS333938, Treatment Set TS128872
  9. Drug

    Fagus grandifolia pollen

    go.drugbank.com/drugs/DB10350
    Approved

    Fagus grandifolia pollen is the pollen of the Fagus grandifolia plant. Fagus grandifolia pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS333938, Treatment Set TS128872
  10. Drug

    Metenkefalin

    go.drugbank.com/drugs/DB12668
    Investigational

    [A203225] It has been shown to reduce chromosomal abberations in patients with multiple sclerosis.